CorMedix (CRMD)
Sells an FDA-approved catheter lock solution and a portfolio of hospital anti-infective drugs across the US.
CorMedix (CRMD) Upgraded to Buy: Here's Why
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
CorMedix Q2 Earnings Call Highlights
CorMedix NASDAQ: CRMD reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed a multiyear commercial supply agreement for DefenCath with an additional large dialysis organization, giving it supply agreements with each of the five largest U.S. dialysis providers.
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix Inc. (NASDAQ:CRMD) shares are rising on Thursday after the company reported strong second-quarter results. The broader market was also slightly higher, with S&P 500 futures up 0.2%.
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.28 per share a year ago.
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus Pharmaceuticals, Inc.
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to 2028, driven by DefenCath adoption and pipeline progress. Key mid-to-long-term catalysts include potential DaVita onboarding, federal market expansion, and pipeline assets like DefenCath TPN and REZZAYO.
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath utilization through changes in federal reimbursement.
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026 and the Jefferies Global Healthcare Conference being held in New York on June 2 – 4, 2026. Details for each fireside chat is as follows:
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix Therapeutics Inc. (NASDAQ:CRMD) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting strong first-quarter results driven by higher utilization of DefenCath and contributions from the acquired Melinta portfolio.
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Q1 Earnings Call Highlights
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments.
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.3 per share a year ago.